Related Experiment Video
Updated: May 23, 2026
05:49
An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies
Published on: November 1, 2024
Models for narcolepsy with cataplexy drug discovery
Alberto K De la Herrán-Arita1, René Drucker-Colín
1Departamento de Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, México.
Expert Opinion on Drug Discovery
|April 4, 2012
Summary
Narcolepsy treatments focus on symptoms, not the underlying orexin circuit. New animal models are crucial for understanding narcolepsy and developing targeted therapies.
Area of Science:
- Sleep Medicine
- Neuroscience
- Pharmacology
Background:
- Narcolepsy is a chronic sleep disorder with disrupted sleep, excessive daytime sleepiness (EDS), and REM sleep abnormalities.
- The condition is linked to genetic alterations affecting the orexin system (ligand or receptor).
- Current treatments are symptomatic and do not address the orexinergic circuit dysfunction.
Purpose of the Study:
- To review current narcolepsy treatments, particularly for cataplexy.
- To discuss the role of narcolepsy models in disease research.
- To highlight the need for novel therapeutic targets.
Main Methods:
- Literature review of current narcolepsy treatments.
- Analysis of the utility of animal models in narcolepsy research.
- Discussion of the orexinergic system's role in narcolepsy.
Main Results:
- Existing narcolepsy treatments are symptom-based and do not target the orexinergic pathway.
- Animal models are essential for studying disease mechanisms and identifying drug targets.
- Understanding narcolepsy pathophysiology is key to developing effective therapies.
Conclusions:
- Novel drug targets for narcolepsy are a primary research focus in sleep medicine.
- Development of new animal models will advance understanding of narcolepsy's underlying causes.
- Future therapies will likely emerge from improved insights into narcolepsy pathophysiology.
Related Concept Videos
01:07Narcolepsy
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
01:24Sleep-Wake Cycles
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).